Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies

Cancer Research
Inge VerbruggeNicole M Haynes

Abstract

It is becoming increasingly evident that radiotherapy may benefit from coincident or subsequent immunotherapy. In this study, we examined whether the antitumor effects of radiotherapy, in established triple-negative breast tumors could be enhanced with combinations of clinically relevant monoclonal antibodies (mAb), designed to stimulate immunity [anti-(α)-CD137, α-CD40] or relieve immunosuppression [α-programmed death (PD)-1]. While the concomitant targeting of the costimulatory molecules CD137 and CD40 enhanced the antitumor effects of radiotherapy and promoted the rejection of subcutaneous BALB/c-derived 4T1.2 tumors, this novel combination was noncurative in mice bearing established C57BL/6-derived AT-3 tumors. We identified PD-1 signaling within the AT-3 tumors as a critical limiting factor to the therapeutic efficacy of α-CD137 therapy, alone and in combination with radiotherapy. Strikingly, all mice bearing established orthotopic AT-3 mammary tumors were cured when α-CD137 and α-PD-1 mAbs were combined with single- or low-dose fractionated radiotherapy. CD8+ T cells were essential for curative responses to this combinatorial regime. Interestingly, CD137 expression on tumor-associated CD8+ T cells was largely restricted t...Continue Reading

Associated Clinical Trials

Mar 9, 2016·Zhang Huo Jun, Zhang Huo Jun

References

Mar 25, 2000·British Journal of Cancer·J LeeE M Lord
Jun 15, 1980·International Journal of Cancer. Journal International Du Cancer·W E Enker, J L Jacobitz
Feb 11, 2004·The Journal of Experimental Medicine·Kazuyoshi TakedaMark J Smyth
Jul 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael H KershawPhillip K Darcy
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James L GulleyWilliam Dahut
Jul 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tomohide YamazakiKo Okumura
May 9, 2006·Nature Medicine·Tomoyasu UnoMark J Smyth
Jul 4, 2007·International Immunology·Taku Okazaki, Tasuku Honjo
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Trina J Stewart, Scott I Abrams
Aug 8, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ailsa J FrewRicky W Johnstone
Oct 7, 2008·Oncogene·T J Stewart, S I Abrams
Jan 20, 2009·Reviews on Recent Clinical Trials·Anita C BellailChunhai Hao
Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Inge VerbruggeMarcel Verheij
May 12, 2009·Immunological Reviews·James L Riley
Jul 4, 2009·The Lancet Oncology·Silvia C Formenti, Sandra Demaria
Jul 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michele W L TengMark J Smyth
Aug 27, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Zahidunnabi DewanSandra Demaria
Feb 17, 2010·Apoptosis : an International Journal on Programmed Cell Death·Christoph PeterKirsten Lauber
Feb 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael A CurranJames P Allison
May 28, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicole M HaynesMark J Smyth
Dec 17, 2010·Journal of Mammary Gland Biology and Neoplasia·Stephen L Shiao, Lisa M Coussens
Mar 4, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ailsa J ChristiansenRicky W Johnstone
Apr 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·John StaggMark J Smyth
Dec 1, 2011·Epigenomics·Inge VerbruggeMichael Bots

❮ Previous
Next ❯

Citations

Jul 9, 2013·Trends in Molecular Medicine·Marco DuranteKathryn D Held
Jan 28, 2014·The Lancet. Respiratory Medicine·Eric Tartour, Laurence Zitvogel
Jan 8, 2013·Journal of the National Cancer Institute·Silvia C Formenti, Sandra Demaria
Feb 5, 2014·Immunotherapy·David B PageHeather L McArthur
May 24, 2014·Journal for Immunotherapy of Cancer·David A SchaerJedd D Wolchok
Dec 17, 2014·Seminars in Oncology·Susan M Hiniker, Susan J Knox
Nov 26, 2015·Nature Reviews. Clinical Oncology·Mark J SmythMichele W L Teng
Dec 17, 2015·Nature Reviews. Clinical Oncology·Peter SavasSherene Loi
Sep 13, 2014·Expert Opinion on Biological Therapy·Ira SuroliaRavi A Madan
Apr 18, 2015·Expert Opinion on Biological Therapy·Jamie HoneychurchTimothy M Illidge
Jan 12, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Amani MakkoukHolbrook E Kohrt
Sep 10, 2013·Seminars in Radiation Oncology·Byron Burnette, Ralph R Weichselbaum
Feb 6, 2013·Cytokine & Growth Factor Reviews·Simone MocellinPierluigi Pilati
Oct 16, 2013·Cancer Letters·Shankar SivaOlga A Martin
Jan 17, 2016·European Journal of Immunology·Alfonso R Sanchez-PauleteIgnacio Melero
Mar 10, 2016·Nature Reviews. Clinical Oncology·Michael B BernsteinJoe Y Chang
Sep 22, 2015·Pharmacology & Therapeutics·Johan M van RooijenElisabeth G E de Vries
Mar 25, 2014·International Journal of Cancer. Journal International Du Cancer·Ann Rita HalvorsenHege Edvardsen
Mar 26, 2014·International Journal of Radiation Oncology, Biology, Physics·Matthew WitekAdam E Snook
Mar 26, 2014·International Journal of Radiation Oncology, Biology, Physics·Christopher A Barker, Michael A Postow
Jan 17, 2015·Cancer Letters·Suresh J HaikerwalNicole M Haynes
Mar 25, 2015·Cancer Letters·Saumil J GandhiAmit Maity
Aug 25, 2015·BMC Medicine·Sathana DushyanthenSherene Loi
Dec 11, 2013·BioMed Research International·Jing ZengPhuoc T Tran
Jun 25, 2015·Nature Reviews. Cancer·Holly E BarkerKevin J Harrington
Apr 22, 2015·The Journal of Clinical Investigation·Camille GuillereyLudovic Martinet
Oct 2, 2013·Oncoimmunology·Christel DevaudMichael H Kershaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.